Trial Profile
First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HS 10241 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Atridia; Jiangsu Hengrui Medicine Co.
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.